Who Should Not Take Mounjaro or Wegovy? A GP's Guide
A UK GP's guide to who should not take Mounjaro (tirzepatide) or Wegovy (semaglutide), who needs extra caution, and the red-flag symptoms that need urgent medical help. Patient information, not medical advice.
How this guide was checked
TreatCompare uses published provider fees, official regulator registers, NHS/PBS/Medicare references where relevant, and the methodology described on our methodology page. If a clinic, provider or reader spots information that is out of date, they can use our corrections page. Prices are point-in-time and can change before booking.
Most useful next step
Compare current Weight Loss options
This guide explains the UK service-cost framework. Continue to provider checks, NHS eligibility and medicine patient information without public prescription-medicine prices.
Continue from this guide
Turn this Weight Loss article into a comparison
Article visitors often need one of three routes next: provider checks, NHS eligibility, or a related medicine information page.
Wegovy (semaglutide) and Mounjaro (tirzepatide) are new weight-loss medicines that can help some people lower their risk of type 2 diabetes, joint pain, and heart disease. A lot of people ask me if these weight-loss injections are right for them, and while they can offer real benefits, they aren't suitable for everyone. Here's a quick guide to who should avoid these medicines, and who needs extra caution.
Who should not take these medications?
There are certain people who are not advised to take either Mounjaro or Wegovy at all. You should not take Mounjaro or Wegovy if you have any of the following:
- Personal or family history of medullary thyroid carcinoma or MEN2: These medicines carry a warning for a rare thyroid cancer called medullary thyroid carcinoma (MTC) and a related condition, Multiple Endocrine Neoplasia type 2 (MEN2) (NICE TA1026/TA875, BNF). If you or a close family member has either of these, these medicines should not be prescribed.
- Allergy to the active ingredient: If you are allergic to tirzepatide (Mounjaro) or semaglutide (Wegovy), or have reacted to any GLP-1 medicine before, you should not take them (MHRA, BNF). Tell your prescriber about any allergies before starting.
- Breastfeeding and Pregnancy: Neither medicine is considered safe during pregnancy or breastfeeding. Both should be stopped before trying to conceive. Your prescriber should discuss contraception options with you, as losing weight can also affect fertility.
- History of pancreatitis: These medicines have been linked to pancreatitis (BNF, MHRA). If you have had pancreatitis, you should not use them.
- Less than 18 years of age: Neither of these medications is currently licensed for use in adolescents or children in the UK (NICE TA1026/TA875, BNF).
Who should use these medicines with caution?
Some people may be able to use these medicines, but will need extra care and regular check-ins with their healthcare team. Caution is needed if you have:
- Severe gastrointestinal conditions: These two medicines work by slowing the rate at which we empty food from the stomach. This, therefore, can lead to worsening of conditions such as severe gastro-oesophageal reflux or Gastroparesis (delayed stomach emptying).
- Liver or kidney disease: Significant liver or kidney problems may require closer monitoring or dose adjustments (BNF, MHRA). Your prescriber will check your liver and kidney function first.
- History of eating disorders: Let your doctor know if you have ever had an eating disorder, as these medicines affect appetite and need careful support (NICE, BNF).
- Diabetic eye disease: Rapid improvement in blood sugar, especially with Wegovy, can worsen diabetic eye disease in the short term (MHRA, NICE TA1028). Tell your prescriber if you have diabetic retinopathy.
- Taking insulin or sulphonylureas: These medicines can lower blood sugar further, so your doses may need adjusting (MHRA, BNF). Make sure your diabetes team and prescriber are aware of all your treatments.
Concerning / red flag symptoms: when to seek medical help
If you have already started Mounjaro or Wegovy and happen to notice any of the following, you need to seek urgent medical attention:
- Severe or persistent abdominal pain, and in particular a pain that spreads to the back, as this could indicate pancreatitis
- Swelling of the face, lips or throat, difficulty breathing or a widespread rash are signs of an allergic reaction.
- Swelling or a lump in the neck, trouble swallowing, or hoarseness could be thyroid issues and should be checked promptly.
- Any sudden vision changes should be reviewed promptly if you have diabetes.
What should a good prescriber do before starting treatment?
Before prescribing, your doctor should review your medical and family history, check your current medications, and arrange blood tests (liver, kidney, and blood sugar). They should ensure you meet the criteria, explain how to take the medication, discuss possible side effects, and tell you when to seek help.
If you have been offered either Wegovy or Mounjaro and you have not received a proper consultation or any questions you have about your suitability for these medicines have not been fully addressed, it is worth seeking a more thorough review before stating.
This article is for general information only and does not constitute personal medical advice. Always speak to a qualified, GMC-registered clinician before starting any prescription medicine.
Data funnel
Help improve UK healthcare price data
TreatCompare gets more useful when readers send real quotes, providers verify listings, and outdated claims are corrected. Submissions are reviewed before publication.
Frequently asked questions
Who should not take Mounjaro or Wegovy?
Mounjaro (tirzepatide) and Wegovy (semaglutide) should not be prescribed to anyone with a personal or family history of medullary thyroid carcinoma (MTC) or MEN2, a known allergy to the active ingredient or any GLP-1 medicine, a history of pancreatitis, or who is pregnant or breastfeeding. They are also not licensed for under-18s in the UK.
Who needs to use Mounjaro or Wegovy with caution?
Extra care and regular monitoring are needed for people with severe gastrointestinal conditions such as gastroparesis or severe reflux, significant liver or kidney disease, a history of eating disorders, diabetic eye disease (retinopathy), or those taking insulin or sulphonylureas, which may need dose adjustment.
What are the red-flag symptoms to seek urgent help for on Mounjaro or Wegovy?
Seek urgent medical attention for severe or persistent abdominal pain (especially spreading to the back), swelling of the face, lips or throat or difficulty breathing, a lump or swelling in the neck, trouble swallowing or hoarseness, or any sudden vision changes if you have diabetes.
What should a prescriber check before starting Mounjaro or Wegovy?
A prescriber should review your medical and family history, check your current medications, and arrange liver, kidney and blood-sugar tests. They should confirm you meet the criteria, explain how to take the medicine and its side effects, and tell you when to seek help.
About the clinical reviewer
Clinical reviewer
Dr Adaugo Nwachukwu is a GMC-registered GP with NHS primary care experience and a clinical focus on preventative medicine, metabolic health and weight management. For TreatCompare, she clinically reviews patient-facing health content for accuracy, balance, patient-safety signposting, prescription-medicine safety and alignment with current UK guidance from the NHS, NICE, MHRA and BNF.
More about the author →Sources & further reading
- NICE TA1026 - Tirzepatide for managing overweight and obesity in adults — NICE technology appraisal guidance for tirzepatide (Mounjaro) in obesity.
- NICE TA875 - Semaglutide for managing overweight and obesity — NICE technology appraisal guidance for semaglutide (Wegovy) in obesity.
- MHRA / emc - Mounjaro (tirzepatide) Summary of Product Characteristics — Licensed product information including contraindications, warnings and cautions.
- MHRA / emc - Wegovy (semaglutide 2.4mg) Summary of Product Characteristics — Licensed product information including contraindications, warnings and cautions.
- British National Formulary (BNF) - Tirzepatide — UK prescribing reference monograph for tirzepatide.
- British National Formulary (BNF) - Semaglutide — UK prescribing reference monograph for semaglutide.
- NHS England - Commissioning guidance for tirzepatide (Mounjaro) in obesity — NHS commissioning and phased-rollout guidance for tirzepatide.
- NHS - Medicines A to Z: Wegovy and Mounjaro — NHS patient information on how the medicines work, side effects and safety.
- MHRA Yellow Card scheme — Report suspected side effects from GLP-1 medicines.
Continue with UK weight-loss cost guidance
Weight Loss Injection Cost UK
Service-cost framework, NHS eligibility, provider checks and patient information for Mounjaro, Wegovy, Ozempic and Nevolat queries.
Lower-Cost Injection Route
NHS access, service fees and provider checks
Mounjaro Price UK Questions
Service fees, NHS access and provider checks
Wegovy Price UK Questions
Service fees, NHS access and dose context
Mounjaro Patient Information
Tirzepatide doses, safety checks and prescriber questions
Wegovy Patient Information
Semaglutide 2.4mg doses, safety checks and NHS route
Related articles
Lower-Cost Weight Loss Injections UK 2026: NHS Access, Service Fees and Provider Checks
Lower-cost weight loss injections UK guide: how to compare private consultation service fees, NHS eligibility, follow-up costs and provider safety checks without public prescription-medicine price tables.
GLP-1 Weight-Management Medicines in the UK: Patient Information (2026)
Patient information about the GLP-1 receptor agonists used for weight management or type 2 diabetes in the UK — Mounjaro, Wegovy, Ozempic, Rybelsus, Nevolat. No prescription-medicine prices.
How to Get Mounjaro in the UK: Patient Information (2026)
Patient information about UK NHS and private routes for Mounjaro (tirzepatide). Not an advertisement and not medical advice.
Mounjaro Price UK 2026: Cost Questions, NHS Access and Provider Checks
Mounjaro price UK guide: why prescription-medicine prices are not displayed, what private service fees to ask about, NHS access and GPhC provider checks.